Acute Effects of Ginger Extract Consumption on Risk Markers of Cardiovascular Disease

Randomized, Controlled Trial of Ginger Extract Consumption for Healthy Males at Risk of Developing Cardiovascular Disease

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02735486

Acronym

G-CVD

Enrollment

Registered

2016-04-12

Start date

2014-02-28

Completion date

2014-08-31

Last updated

2016-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Keywords

Ginger, blood pressure, flow mediated dilatation

Brief summary

The primary aim of the study was to investigate the acute effect of ginger drink consumption on the risk markers of cardiovascular disease.

Detailed description

A randomized, single-blind human intervention study involving 22 healthy male volunteers was designed to investigate the acute effects of ginger drink consumption on risk markers of cardiovascular disease (CVD). The primary outcome measure is reduction in blood pressure while the secondary outcome measures are improvement in flow mediated dilatation (FMD) and changes in plasma biochemical profile parameters related to CVD. Participants were given 300 ml of ginger extract or water (placebo) with breakfast, followed by a lunch at 2 hours on two visits separated by 2 weeks. Blood and urine samples were collected at regular intervals as well as blood pressure measurement done during the two visits. Vascular function was measured by flow mediated dilatation (FMD) and pulse wave velocity (PWV) at baseline, 2 and 4 hours after the the consumption of the study drink and placebo. The blood and urine samples were analysed for changes in lipid profile and other markers of CVD.

Interventions

DIETARY_SUPPLEMENTGinger drink

300 ml ginger drink

DIETARY_SUPPLEMENTPlacebo: Super pure water

Placebo: Super pure water

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

BASIC_SCIENCE

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

MALE

Age

30 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Apparently healthy males, * Age (30 - 65) years, * Not diabetic or plasma glucose \> 7 or on anti-diabetic drugs and not on anti- hypertensive drugs. * Subjects \< 10% risk of cardiovascular disease

Exclusion criteria

* Women, * Men younger than 30 years and older that 65 years, * Men who are sick or on anti-diabetic and anti-hypertensive drugs. * Men who have history of heart attack or stroke within the last 12 months * Men who are on lipids lowering drugs

Design outcomes

Primary

Measure	Time frame	Description
Reduction in blood pressure (BP)	Six (6) hours	Reduction in blood pressure (BP)

Secondary

Measure	Time frame	Description
Flow mediated dilatation	Six (6) hours	Improvement in vascular function measured as percentage (%) increase in FMD

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026